gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 05 Nov 2015.

RAD51 homolog C

This gene is a member of the RAD51 family of related genes, which encode strand-transfer proteins thought to be involved in recombinational repair of damaged DNA and in meiotic recombination. This gene product interacts with two other DNA repair proteins, encoded by RAD51B and XRCC3, but not with itself. The protein copurifies with XRCC3 protein in a complex, reflecting their endogenous association and suggesting a cooperative role during recombinational repair. This gene is one of four localized to a region of chromosome 17q23 where amplification occurs frequently in breast tumors. Overexpression of the four genes during amplification has been observed and suggests a possible role in tumor progression. Alternative splicing has been observed for this gene and two variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: Rad51, XRCC3, poly(A)-binding protein, RAD51B, Iris
Papers on RAD51C
Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
Chenevix-Trench et al., Brisbane, Australia. In J Med Genet, 03 Dec 2015
RESULTS: We found 31 putative deleterious mutations in 7 known breast cancer susceptibility genes (TP53, PALB2, ATM, CHEK2, CDH1, PTEN and STK11) in 45 cases, and 22 potential deleterious mutations in 31 cases in 8 other genes (BARD1, BRIP1, MRE11, NBN, RAD50, RAD51C, RAD51D and CDK4).
Genetic testing for RAD51C mutations: in the clinic and community.
Narod et al., Toronto, Canada. In Clin Genet, 31 Oct 2015
Germline mutations in RAD51C have been identified in about 1% of hereditary breast and ovarian cancer families.
Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
Pharoah et al., Manchester, United Kingdom. In J Clin Oncol, 10 Oct 2015
PURPOSE: The aim of this study was to estimate the contribution of deleterious mutations in the RAD51B, RAD51C, and RAD51D genes to invasive epithelial ovarian cancer (EOC) in the population and in a screening trial of individuals at high risk of ovarian cancer.
Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart.
Nagaraju et al., Bengaluru, India. In Nucleic Acids Res, 09 Oct 2015
RAD51C and XRCC3 promote the restart of stalled replication in an ATP hydrolysis dependent manner by disengaging RAD51 and other RAD51 paralogs from the halted forks.
Screening of HELQ in breast and ovarian cancer families.
Nevanlinna et al., Helsinki, Finland. In Fam Cancer, 08 Oct 2015
Two components of the complex, RAD51C and RAD51D, increase the risk of ovarian cancer especially, and the other two, RAD51B and XRCC2 have been associated with breast cancer risk.
RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
Brankovic-Magic et al., Belgrade, Serbia. In Cancer Biomark, Sep 2015
BACKGROUND: In 2010 an important finding was published showing that heterozygous mutations in RAD51C were highly penetrant and were able to confer an increased risk for breast and ovarian cancers.
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Fasching et al., Rochester, United States. In J Clin Oncol, Mar 2015
Deleterious mutations in 15 other predisposition genes were detected in 3.7% of patients, with the majority observed in genes involved in homologous recombination, including PALB2 (1.2%) and BARD1, RAD51D, RAD51C, and BRIP1 (0.3% to 0.5%).
Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management.
Weitzel et al., Duarte, United States. In Front Oncol, Dec 2014
We also discuss specific challenging cases that arose during this period involving abnormalities in the genes: CDH1, TP53, PMS2, PALB2, CHEK2, NBN, and RAD51C.
[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Takeshima et al., In Gan To Kagaku Ryoho, Nov 2014
Recently, candidate genes other than BRCA1/2, such as RAD51C, PALB2, and BRIP1, have been identified for hereditary breast cancers.
PALB2: the hub of a network of tumor suppressors involved in DNA damage responses.
Andreassen et al., Cincinnati, United States. In Biochim Biophys Acta, Aug 2014
More recently, PALB2 has been found to bind the RAD51 paralog, RAD51C, as well as the translesion polymerase pol η, both of which are tumor suppressors with functions in HR.
Meta-analysis identifies four new loci associated with testicular germ cell tumor.
Nathanson et al., Bethesda, United States. In Nat Genet, 2013
P = 4.04 × 10(-9)), a locus that includes TEX14, RAD51C and PPM1E.
Hereditary genes and SNPs associated with breast cancer.
Nasiri et al., Mashhad, Iran. In Asian Pac J Cancer Prev, 2012
The most important loci which include mutations are; BRCA1, BRCA2, PTEN, ATM, TP53, CHEK2, PPM1D, CDH1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PMS1, PMS2, BRIP1, RAD50, RAD51C, STK11 and BARD1.
Breast cancer genes: beyond BRCA1 and BRCA2.
Vega et al., Spain. In Front Biosci, 2012
Moreover, a combination of family-based and population-based approaches indicated that genes involved in DNA repair, such as CHEK2, ATM, BRIP1 (FANCJ), PALB2 (FANCN) and RAD51C (FANCO), are associated with moderate BC risk.
High sensitivity for BRCA1/2 mutations in breast/ovarian kindreds: are there still other breast/ovary genes to be discovered?
Evans et al., In Breast Cancer Res Treat, 2012
the contribution of RAD51C and RAD51D gene mutations to an inherited high risk of ovarian cancer is very small
Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.
Claes et al., Gent, Belgium. In Breast Cancer Res Treat, 2012
RAD51C germline mutations in families with a history for both breast and ovarian cancer appear to have a low prevalence with the exception of some founder mutations.
Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility.
Nagaraju et al., Bengaluru, India. In J Biol Chem, 2012
unravel the critical role of RAD51C in the FA pathway of ICL repair and as a tumor suppressor.
Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.
Campbell et al., Melbourne, Australia. In Hum Mutat, 2012
Missense variant of RAD51C (p.Gly264Ser) is a moderate penetrance allele in high-risk breast and ovarian cancer families.
Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Rahman et al., United Kingdom. In Nat Genet, 2011
Recently, RAD51C mutations were identified in families with breast and ovarian cancer.
RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
Neuhausen et al., Duarte, United States. In Plos One, 2010
RAD51C is a rare breast and ovarian cancer susceptibility gene.
Fanconi anemia and breast cancer susceptibility meet again.
Levy-Lahad, Jerusalem, Israel. In Nat Genet, 2010
A new study reports biallelic mutations in RAD51C in a Fanconi anemia-like disorder, while a second study reports monoallelic mutations in the same gene associated with increased breast cancer risk.
share on facebooktweetadd +1mail to friends